CCR2 and hepatocellular carcinoma: Aptamers targeting of CCL2/CCR2 and CCR2 expression using small-molecule antagonists, neutralizing antibodies, or RNA aptamer-based inhibitors have demonstrated efficacy to repress angiogenesis in subcutaneous HCC xenografts and endogenous liver tumors (63, 64).